RESEARCH

BMC Gastroenterology



A novel nomogram and risk stratification system predicting the cancer-specific survival of patients with gastric neuroendocrine carcinoma: a study based on SEER database and external validation

Xue Song¹, Yangyang Xie² and Yafang Lou^{1*}

Abstract

Background Gastric neuroendocrine carcinoma (GNEC) is a rare histology of gastric cancer. The retrospective study was designed to construct and validate a nomogram for predicting the cancer-specific survival (CSS) of postoperative GNEC patients.

Methods Data for 28 patients from the Hangzhou TCM Hospital were identified as the external validation cohort. A total of 1493 patients were included in the SEER database and randomly assigned to the training group (1045 patients) and internal validation group (448 patients). The nomogram was constructed using the findings of univariate and multivariate Cox regression studies. The model was evaluated by consistency index (C-index), calibration plots, and clinical net benefit. Finally, the effect between the nomogram and AJCC staging system was compared by net reclassification index (NRI) and integrated discrimination improvement (IDI).

Results Age, gender, grade, T stage, N stage, metastasis, primary site, tumor size, RNE, and chemotherapy were incorporated in the nomogram. The C-indexes were 0.792 and 0.782 in the training and internal verification sets. The 1-, 3-, and 5-year CSS predicted by the nomogram and actual measurements had good agreement in calibration plots. The 1-, 3-, and 5-year NRI were 0.21, 0.29, and 0.37, respectively. The 1-, 3-, and 5-year IDI values were 0.10, 0.12, and 0.13 (P < 0.001), respectively. In 1-, 3-, and 5-year CSS prediction using DCA curves, the nomogram outperformed the AJCC staging system. The nomogram performed well in both the internal and external validation cohorts.

Conclusion We developed and validated a nomogram to predict 1-, 3-, and 5-year CSS for GNEC patients after surgical resection. This well-performing model could help doctors enhance the treatment plan.

Keywords Gastric cancer, SEER program, Nomogram, Risk stratification, AJCC (TNM) staging system

*Correspondence: Yafang Lou szyylouyafang@163.com ¹Department of Respiratory and Critical Care Medicine, Hangzhou TCM Hospital, Zhejiang Chinese Medical University, #453, Tiyuchang Road, Xihu District, Hangzhou 310000, Zhejiang province, China



²Department of General Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310000, Zhejiang province, China

© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Gastric cancer (GC) is a highly heterogeneous malignancy with several pathologies exhibiting markedly varied molecular patterns, tumor behavior, and prognoses [1]. Gastric neuroendocrine carcinoma (GNEC) is a rare histological type of GC that affects 0.1-0.6% of all patients and has been on the rise in recent decades [2]. GNEC is made up of poorly differentiated endocrine cells, which present poor prognoses and tendencies to spread, and bleeding is an important cause of patient mortality [3, 4]. Lin et al. indicated that the survival of GNEC patients was much shorter than gastric adenocarcinoma [5]. Radical surgery, as the primary treatment for GNEC, is the only possible cure method. However, compared with GC patients, the prognoses of postoperative GNEC patients remained unsatisfying [6]. Therefore, determining postoperative prognostic variables is crucial for selecting treatment modalities and surveillance plans.

American Joint Committee on Cancer (AJCC) TNM staging system has played an essential role in predicting the prognosis of GNEC [7, 8]. However, other variables that are not considered by the AJCC staging system, such as age, gender, tumor location, size, grade, and treatment, may also have an influence on the prognosis in GNEC patients [9–11]. For this reason, developing individualized treatment plans and predicting the prognosis of high-risk patients require a more trustworthy model in conjunction with effective clinicopathological aspects. Due to its simplicity and intuitiveness, nomogram, a graphical calculation model with continuous scales to assess the likelihood of a specific result, has demonstrated a more accurate predictive ability than conventional staging systems [12-14]. However, no similar research has been proposed to predict postoperative survival in GNEC patients.

Based on the Surveillance, Epidemiology, and End Results (SEER) database, the study was directed to establish and validate a nomogram with a new risk stratification system for predicting the cancer-specific survival (CSS) of postoperative GNEC patients. The model's performance was also compared with the AJCC 8th staging system.

Materials and methods

Data source and patient selection

The data was retrieved from the SEER database during 2010–2015 and analyzed retrospectively. External validation data was obtained from the Hangzhou TCM Hospital between January 2012 and December 2016. This research was carried out in line with the Helsinki Declaration. Participation in this study did not need written informed consent, as required by national law and institutional norms. The Ethics Committee of the Hangzhou TCM Hospital examined and approved the experiment involving human participants.

The third edition of the International Classification of Diseases for Oncology (ICD-O-3) was used to identify cases of GNEC. 8012/3, 8013/3, 8041/3, 8042/3, 8043/3, 8044/3, 8244/3, and 8246/3 were the histological codes. The inclusion criteria were as follows: [1] older than 18 years old; [2] GNEC was the only cancer diagnosis; [3] a history of primary tumor resection; [4] the survival time was more than one month. Patients with incomplete clinicopathological information, treatment, and unknown duration of survival were excluded from the research. The detailed selection process was shown in Fig. 1.

Clinicopathological variables

The following characteristics were extracted from the SEER database: year of diagnosis, gender, age, race, marital status, grade, AJCC stage, T stage, N stage, M stage, primary site, tumor size, regional nodes examined (RNE), surgery, radiation therapy, chemotherapy, survival time and vital status. Patients were categorized according to the primary site (cardia, distal site, middle site, and overlapping/NOS), tumor size (≤ 2 cm, ≤ 5 cm, and >5 cm), and RNE (0, 1–15, and ≥ 16). The GNEC patients were converted to the 8th edition of the AJCC TNM staging system based on the 7th edition in the SEER database. In the research, CSS was regarded as the endpoint. It was defined as the period from diagnosis to cancer-related mortality.

Statistical analysis

All patients were randomized into two groups with a 7:3 ratio. The training group was employed to construct the nomogram, while the internal and external validation groups were applied to validate it. Both univariate and multivariate Cox regressions were performed to calculate the significant parameters (P < 0.05). A predictive nomogram was then established to calculate the 1-, 3-, and 5-year CSS for postoperative GNEC cases.

To assess discriminative capabilities, the consistency index (C-index) and the time-dependent area under the curve (AUC) were computed using bootstrapping. The higher value of the C-index and AUC denoted greater predictive ability. The 1-, 3-, and 5-year calibration plots (1,000 bootstrap resamples) were used to compare the predicted CSS with what was actually observed. The ideal prediction was shown to be the 45-degree line.

The net benefit for a set of threshold probabilities was calculated using decision curve analysis (DCA), which allowed researchers to test how well the model would function as a clinical decision-making tool. The optimum risk score cutoff value was utilized to create a novel risk stratification approach that divides patients into low-, middle-, and high-risk groups using the X-tile software.



Fig. 1 Flow diagram of the selection of eligible GNEC patients

To compare the variations in CSS among patients in various risk stratification groups, Kaplan-Meier (KM) curves and log-rank tests were used. The C-index, Net Reclassification Index (NRI), Integrated Discrimination Improvement (IDI), and DCA were used to evaluate the new model's enhanced predictive potential and effectiveness.

All statistical computations and visualizations were done using R software version 4.1.2 (http://www.r-project.org). A two-tailed P<0.05 was statistically significant.

Results

Clinicopathological characteristics

1493 GNEC patients were enrolled and divided into the training group (1045 patients) and the internal validation group (448 patients). The 28 patients from the Hangzhou TCM Hospital who made up the external validation cohort were identified. The demographic and clinical characteristics of the patients from the SEER database were shown in Table 1. The two groups did not substantially vary in demographic or clinical factors (all P>0.05).

Univariate and multivariate cox regression analysis

The univariate Cox regression performed in the training group indicated that age, gender, grade, T stage, N stage, metastasis, primary site, tumor size, RNE, and chemotherapy were significant prognostic parameters for GNEC patients (P < 0.05). The important variables identified by univariate Cox regression were then incorporated in multivariate Cox regression analysis, demonstrating that each of these components was an independent variable (Table 2).

Development and internal validation of the nomogram

Finally, ten variables screened by multivariate Cox regression were applied to develop the nomogram for predicting the 1-, 3-, and 5-year CSS in GNEC patients

N=1493 N=1045 N=448 Variat diagnois 0.242 X01-101 77 (50.1%) 512 (46.0%) 23 (47.3%) 2013 213 (47.3%) 525 (57.5%) 0.233 2013 213 (47.3%) 525 (57.5%) 0.233 200 144 (28.4%) 20 (72.94%) 117 (26.1%) 0.233 500 1669 (71.6%) 736 (70.6%) 331 (73.9%) 62 6ender 576 (82.6%) 584 (37.7%) 182 (10.0%) 386 (10.2%) Female 576 (82.6%) 584 (32.9%) 226 (02.4%) 60 Nor-White 630 (42.2%) 458 (43.8%) 172 (28.9%) 50 Nor-White 630 (42.2%) 458 (43.8%) 191 (42.6%) 60 Marind status 0.066 0.065 (43.2%) 191 (42.6%) 61 Marind status 0.066 0.065 (43.2%) 191 (42.3%) 61 Marind status 0.066 (43.3%) 191 (42.3%) 191 (42.6%) 61 Marind status 0.02.0%) 237 (57.4%) 197 (16.7%)	Characteristics	All	Training	Validation	P value
Year at diagnosis 10.000 10.000 10.000 10.000 00.0000 00.00000 00	characteristics	N=1493	N=1045	N=448	
manual /// (50.0%) 512 (49.0%) 235 (52.5%) manual 2013 2015 // 46 (50.0%) 533 (51.0%) 211 (47.5%)	Year at diagnosis				0.242
Date Date Date Date Age	2010-1012	747 (50.0%)	512 (49.0%)	235 (52 5%)	0.212
Date of the section of the sectin of the section of the section of the section of the se	2013-2015	746 (50.0%)	533 (51.0%)	213 (47 5%)	
sol 424 (28.4%) 307 (29.4%) 117 (26.1%) 33 sol 1009 (71.0%) 738 (70.0%) 331 (72.9%) 331 (72.9%) sonder	Age	7.18 (30.070)	333 (31.876)	213 (11.376)	0.223
Join (Jose) Join (Jose) Join (Jose) Sol Jose) Jose) Jose) Gender	<60	474 (28.4%)	307 (29.4%)	117 (26.1%)	0.225
No. No. No. No. No. No. Gender	>60	1069 (71.6%)	738 (70.6%)	331 (73.9%)	
Jamba 576 (38.6%) 394 (37.7%) 182 (40.6%) Male 97 (61.4%) 65 (62.3%) 26 (69.4%) Race	Condor	1009 (71.070)	/ 30 (/ 0.070)	331 (73.270)	0.315
Initial D1 (0000) D3 (0000) D3 (0000) Nale D1 (01000) D3 (0000) D3 (0000) Race	Eemalo	576 (38 6%)	304 (37 7%)	182 (40,6%)	0.515
mate b< b< b b< b< b< b<	Mala	017 (61 404)	651 (62 204)	762 (40.0%)	
mate mate mate mate While 863 (57.8%) SP7 (56.2%) 276 (61.6%) 127 (38.4%) Non-White 30 (62.2%) 458 (43.8%) 172 (38.4%) 0 Marital status 916 (61.4%) 659 (63.1%) 257 (57.4%) 0 Unmarried 916 (61.4%) 659 (63.1%) 257 (57.4%) 0 Grade 258 (17.3%) 183 (17.5%) 75 (16.7%) 0 Ill 560 (37.5%) 38 (75.7%) 173 (38.6%) 0 NAC 560 (37.5%) 38 (75.7%) 173 (38.6%) 0 NAC 560 (37.5%) 38 (62.2%) 150 (33.5%) 0 ALC 486 (32.6%) 32 (02.7%) 133 (29.7%) 0 Ill 454 (30.4%) 32 (02.0%) 12 (23.8%) 0 Ill 177 (28%) 29 (7.6%) 38 (8.5%) 0 Ill 17 (2.8%) 20 (21.0%) 33 (29.7%) 13 (29.7%) No 17 (2.8%) 29 (7.6%) 38 (8.5%) 0 <	Paco	917 (01.470)	051 (02.5%)	200 (39.470)	0.050
Winter 60 (12.8%) 61 (62.8%) 27 (18.4%) Maried 630 (42.2%) 458 (43.9%) 17 (28.4%) Maried 97 (18.6%) 36 (6.6%) 191 (42.6%) Grade - 0.65 Grade - 0.625 Ill 455 (43.2%) 451 (43.2%) 194 (43.3%) Ill 645 (43.2%) 35 (7.0%) 173 (43.6%) V 30 (2.0%) 24 (2.3%) 6 (1.3%) ACC stage - 0.854 I 465 (0.26%) 36 (0.2.%) 133 (2.9.%) XC stage - 0.853 I 476 (0.2.%) 30 (2.0%) 132 (2.9.%) XI 476 (0.2.%) 30 (2.0.%) 132 (2.9.%) XI 177 (2.8.3%) 0.9 (2.9.%) 133 (2.9.%) XI 476 (0.9.%) 32 (2.0.%) 32 (2.9.%) XI stage - 0.833 T1 stage 264 (17.7%) 19 (18.3%) 13 (1.8.%) XI stage - 0.509 N	White	962 (57 904)	597 (56 204)	276 (61 604)	0.059
Non-Write 050 (N2.2%) 050 (N2.2%) 050 (N2.2%) 050 (N2.2%) Marikal status 0.066 Marikal status 577 (38.6%) 358 (36.3%) 257 (57.4%) Unmarried 977 (38.6%) 183 (17.5%) 97 (42.6%) 0.026 I married 258 (17.3%) 183 (17.5%) 97 (67.4%) 0.026 II married 560 (37.5%) 377 (67.0%) 173 (38.6%) 0.026 V AC Stage 73 (38.6%) 377 (67.0%) 133 (29.7%) II Married 456 (32.6%) 321 (30.7%) 133 (29.7%) 0.025 II Married 456 (29.0%) 391 (29.0%) 133 (29.7%) 0.027 II Married 456 (29.0%) 391 (29.0%) 133 (29.7%) 0.033 (50.1%) II Married 170 (29.0%) 191 (18.3%) 73 (16.3%) 0.01 II Married 170 (29.9%) 338 (22.3%) 100 (33.5%) 0.01 II Married 170 (29.0%) 133 (29.7%) 100 (13.3%) 0.01 II Married 170 (29.9%) 133 (29.7%	Winte	620 (42 20%)	367 (30.2%) 459 (43.9%)	270 (01.0%)	
Mariled 00000 Mariled 916 (61,4%) 659 (63,1%) 257 (57,4%) Ummariled 577 (38,6%) 386 (36,5%) 191 (42,6%) Grade 0.000 Grade 0.000 II 645 (43,2%) 453 (47,2%) 194 (43,3%) III 645 (43,2%) 387 (67,0%) 173 (38,6%) V 030 (20,5%) 387 (67,0%) 173 (38,6%) ALCC stage 036 (32,2%) 153 (32,5%) 153 (32,5%) III 454 (30,4%) 314 (30,7%) 133 (29,7%) 033 (21,2%) III 454 (30,4%) 390 (29,6%) 133 (29,7%) 033 (21,2%) III 454 (20,4%) 390 (29,6%) 133 (29,7%) 033 (21,2%) T stage 0.000 133 (29,7%) 033 (23,2%) 133 (29,7%) T stage 0.000 140 (21,8%) 33 (21,9%) 033 (23,2%) N1 317 (21,2%) 327 (51,4%) 320 (21,5%) 034 (21,2%) 0.000 N1	Non-white	030 (42.2%)	438 (43.8%)	172 (38.4%)	0.000
Martheod 95 (05.1 %) 95 (05.1 %) 95 (05.1 %) 95 (05.1 %) Grade 0.626 Grade 0.626 0.626 I 0.63 (05.9%) 183 (17.5%) 0.74 (16.7%) 0.026%) III 0.60 (07.5%) 387 (07.0%) 194 (07.3%) 0.026%) ACC stage 0.63 (07.9%) 386 (07.2%) 0.027%) III 0.60 (07.5%) 336 (07.0%) 130 (03.5%) 0.027%) III 466 (07.2%) 309 (02.9%) 127 (28.3%) 0.027%) III 456 (07.9%) 388 (07.9%) 338 (07.3%) 0.0329%) III 456 (07.9%) 398 (07.9%) 338 (07.3%) 0.0329%) III 456 (07.9%) 398 (07.9%) 338 (07.3%) 0.0329%) III 457 (07.9%) 398 (07.9%) 338 (07.3%) 0.0329%) III 458 (07.9%) 398 (07.9%) 338 (07.3%) 0.0329%) III 458 (07.9%) 398 (07.9%) 338 (07.3%) 0.0329%)	Marriad	016/61/00/			0.066
Ommanie SP/ (380%) Bits (45.%) Bits (45.%) Grade	Mamed	910 (01.4%)	059 (03.1%)	257 (57.4%)	
Grade Unit of the second	Unmarried	577 (38.6%)	386 (36.9%)	191 (42.6%)	0.626
I 258 (1/.3%) 153 (1/.3%) 57 (16.7%) III 656 (37.5%) 387 (37.0%) 173 (38.6%) IV 30 (2.0%) 24 (2.3%) 173 (38.6%) ACC stage 12 (2.3%) 150 (33.5%) 356 (32.0%) ACC stage 336 (32.2%) 130 (2.9.7%) 336 (32.9%) III 466 (32.6%) 321 (30.7%) 33 (2.9.7%) III 466 (32.6%) 309 (29.0%) 32 (2.9.3%) V 117 (2.8%) 79 (7.6%) 38 (8.5%) T stage 71 (2.8%) 304 (29.1%) 133 (29.7%) T stage 133 (29.7%) 333 (32.9%) 51 (5.3.5%) T stage 133 (29.7%) 328 (2.5%) 333 (32.9%) T stage 133 (29.7%) 328 (2.5%) 333 (29.7%) T stage 12 (2.0.4%) 150 (3.3.5%) 51 (3.5%) T stage 21 (2.0.3%) 133 (29.7%) 51 (5.3.5%) T stage 21 (2.0.3%) 133 (2.9.7%) 51 (5.3.5%) T stage 21 (2.0.3%) 133 (2.9.7%) 51 (5.3.5%) <td>Grade</td> <td></td> <td></td> <td></td> <td>0.626</td>	Grade				0.626
III 64b (43,2%) 451 (43,2%) 194 (43,3%) 194 (43,3%) III 50 (37,5%) 37 (37,0%) 13 (36,6%) IV 30 (20%) 24 (2.3%) 6(1.3%) ACCC stage 150 (33,5%) 150 (33,5%) III 486 (32,0%) 321 (30,7%) 133 (29,7%) III 436 (29,2%) 309 (29,6%) 127 (28,3%) V 117 (7,8%) 390 (29,6%) 127 (28,3%) V 117 (7,8%) 304 (29,1%) 133 (29,7%) T stage 537 (51,4%) 334 (32,3%) 150 (33,5%) T stage 122 (20,3%) 22 (20,5%) 0 T 4 42 (0,4%) 23 (20,4%) 150 (33,5%) T 4 12 (20,3%) 230 (51,3%) 0 N 430 767 (51,4%) 537 (51,4%) 24 (23,4%) 0 N 430 12 (12,9%) 140 (12,5%) 140 (12,5%) 0 N 430 12 (12,9%) 140 (12,5%) 160 (13,4%) 0 N 430 12 (12,9%) 140 (12,5%) 160 (13	1	258 (17.3%)	183 (17.5%)	/5 (16./%)	
III SAO (37.5%) 34/ (37.0%) 17.3 (38.6%) IV 30 (2.9%) 24 (2.3%) 6 (1.3%) ALCC stage	 	645 (43.2%)	451 (43.2%)	194 (43.3%)	
IV24 (2.9%)6 / 4.9%)ACC stage		560 (37.5%)	387 (37.0%)	173 (38.6%)	
AJCC stage	IV	30 (2.0%)	24 (2.3%)	6 (1.3%)	
I 486 (32.6%) 336 (32.9%) 150 (33.5%) II 454 (00.4%) 321 (00.7%) 133 (29.7%) III 436 (92.9%) 309 (29.6%) 127 (28.3%) IV 117 (7.8%) 309 (29.6%) 133 (29.7%) Tstage	AJCC stage				0.854
III 454 (30.4%) 321 (30.7%) 132 (29.7%) III 436 (29.2%) 309 (29.6%) 127 (28.3%) V 17 (7.8%) 79 (7.6%) 38 (8.5%) T stage 79 (7.6%) 338 (32.0%) 333 (32.0%) T1 437 (29.3%) 304 (29.1%) 73 (63.3%) T2 264 (17.7%) 318 (32.3%) 150 (33.5%) T4 304 (20.4%) 212 (20.3%) 50 (33.5%) T4 304 (20.4%) 212 (20.3%) 20 (35.5%) Natage 20 (71.3%) 230 (51.3%) 20 (35.5%) N1 317 (21.2%) 213 (20.4%) 104 (32.2%) N2 02 (13.5%) 148 (14.2%) 54 (12.1%) N2 02 (13.5%) 148 (14.2%) 54 (12.1%) N2 02 (13.5%) 148 (14.2%) 54 (12.1%) N3 02 (13.5%) 148 (14.2%) 54 (12.1%) N4 17 (2.8%) 76 (69.2.4%) 14 (10 (9.4%) 56 (13.6%) N1 17 (7.8%) 76 (69.2.4%) 16 (10 (15.5%) 56 (10		486 (32.6%)	336 (32.2%)	150 (33.5%)	
III 436 (22,9%) 309 (29,6%) 127 (28,3%) IV 177 (28,3%) 308 (8,5%) 308 (8,5%) Tstage 437 (29,3%) 304 (29,1%) 133 (29,7%) 68.33 T2 264 (17,7%) 191 (18,3%) 73 (16,3%) 73 T3 488 (32,7%) 338 (32,3%) 150 (33,5%) 74 Nage 202 (0,5%) 202 (0,5%) 74 Nstage 767 (51,4%) 337 (51,4%) 230 (51,3%) 75 N1 317 (21,2%) 213 (20,4%) 104 (23,2%) 75 N2 202 (13,5%) 148 (14,2%) 64 (11,4%) 76 N3 202 (13,5%) 148 (14,2%) 64 (12,4%) 76 N4 177 (28,3%) 148 (14,2%) 64 (12,4%) 76 N4 177 (28,3%) 148 (14,2%) 64 (12,4%) 76 N4 177 (28,3%) 66 (92,4%) 410 (91,5%) 76 N4 177 (28,3%) 96 (94,9%) 410 (91,5%) 76 N1 17 (28,4%) <	II	454 (30.4%)	321 (30.7%)	133 (29.7%)	
IV 117 (7.8%) 79 (7.6%) 38 (8.5%) T stage		436 (29.2%)	309 (29.6%)	127 (28.3%)	
Tstage 0.833 T1 4 437 (29.3%) 304 (29.1%) 133 (29.7%) T2 264 (17.7%) 191 (18.3%) 73 (16.3%) T3 4 88 (32.7%) 383 (32.3%) 150 (33.5%) T4 304 (20.4%) 212 (20.3%) 92 (20.5%) Nstage 767 (51.4%) 537 (51.4%) 230 (51.3%) N1 4 317 (21.2%) 133 (20.4%) 104 (23.2%) N2 202 (13.5%) 148 (14.2%) 54 (12.1%) N2 202 (13.5%) 147 (14.1%) 60 (13.4%) N4 45 (25.2%) 147 (14.1%) 60 (13.4%) M1 17 (28.9%) 96 (92.4%) 410 (91.5%) M1 137 (69.2%) 96 (92.4%) 410 (91.5%) M2 137 (69.2%) 96 (92.4%) 410 (91.5%) M2 137 (69.2%) 96 (92.4%) 167 (37.3%) <td>IV</td> <td>117 (7.8%)</td> <td>79 (7.6%)</td> <td>38 (8.5%)</td> <td></td>	IV	117 (7.8%)	79 (7.6%)	38 (8.5%)	
T1 437 (29.3%) 304 (29.1%) 133 (29.7%) T2 264 (17.7%) 191 (18.3%) 73 (16.3%) T3 488 (32.7%) 338 (32.3%) 150 (33.5%) T4 304 (20.4%) 338 (32.3%) 150 (33.5%) Nstage 507 (51.4%) 202 (0.5%) Nstage 230 (51.3%) 507 (51.4%) 230 (51.3%) N1 317 (21.2%) 213 (20.4%) 104 (23.2%) N2 202 (13.5%) 148 (14.2%) 54 (12.1%) N3 207 (13.9%) 148 (14.2%) 54 (12.1%) N4 107 (13.9%) 147 (14.1%) 63 (41.0 %) N4 376 (52.2%) 148 (14.2%) 54 (12.1%) Mitandsi 176 (92.2%) 96 (92.4%) 410 (91.5%) Mitandsite 176 (92.2%) 96 (92.4%) 410 (91.5%) Mitandsite 176 (92.2%) 96 (92.4%) 160 (91.5%) 36 (56.1%)	T stage				0.833
T2 264 (17.%) 191 (18.3%) 73 (16.3%) T3 488 (32.%) 338 (32.3%) 150 (33.5%) T4 30 (20.4%) 21 (20.3%) 20 (20.5%) Nstage 76 (51.4%) 537 (51.4%) 230 (51.3%) N1 317 (21.2%) 213 (20.4%) 104 (23.2%) N2 202 (13.5%) 148 (14.2%) 60 (13.4%) N2 202 (13.5%) 148 (14.2%) 60 (13.4%) N2 202 (13.5%) 148 (14.2%) 60 (13.4%) N3 207 (13.9%) 147 (14.1%) 60 (13.4%) Metastasis 207 (13.9%) 147 (14.1%) 60 (13.4%) Mota 176 (92.2%) 79 (692.4%) 410 (91.5%) M1 177 (28.%) 79 (7.6%) 38 (8.5%) M1 174 (28.4%) 407 (38.9%) 42 (9.4%) Distal site 574 (38.4%) 407 (38.5%) 167 (37.3%) Middle site 54 (36.7%) 373 (35.7%) 175 (39.1%) 175 (39.1%) Sital site 54 (36.6%) 373 (35.7%) 123 (27.5%) 124 (27.5%) site 54 (36.9%) 323 (21.	T1	437 (29.3%)	304 (29.1%)	133 (29.7%)	
T3 488 (32,7%) 338 (32,3%) 150 (33,5%) T4 304 (20,4%) 212 (20,3%) 92 (20,5%) Nstage 767 (51,4%) 537 (51,4%) 230 (51,3%) N1 317 (21,2%) 131 (20,4%) 104 (23,2%) N2 02 (13,5%) 148 (14,2%) 54 (12,1%) N2 02 (13,5%) 147 (14,1%) 60 (13,4%) N4 04,2%) 54 (12,1%) 61 M4 17 (7,8%) 147 (14,1%) 60 (13,4%) M1 17 (7,8%) 79 (7,6%) 38 (8,5%) M1 117 (7,8%) 96 (92,4%) 410 (91,5%) M1 147 (92,9%) 96 (92,4%) 410 (91,5%) M1 147 (7,8%) 79 (7,6%) 38 (8,5%) M1 147 (7,8%) 96 (92,4%) 410 (91,5%) Gradia 140 (94,9%) 98 (9,4%) 42 (9,4%) M1 147 (7,8%) 98 (9,4%) 167 (37,3%) Middle site 54 (36,5%) 167 (16,0%) 167 (37,3%) Middle site 54 (36,6%) 33 (35,7%) 157 (39,1%) Se cm 64 (40,5%)<	T2	264 (17.7%)	191 (18.3%)	73 (16.3%)	
T4 304 (20.4%) 212 (20.3%) 92 (20.5%) N stage	Т3	488 (32.7%)	338 (32.3%)	150 (33.5%)	
Nstage 0.00 767 (51.4%) 537 (51.4%) 230 (51.3%) N1 317 (21.2%) 213 (20.4%) 104 (23.2%) N2 202 (13.5%) 148 (14.2%) 54 (12.1%) N3 202 (13.5%) 148 (14.2%) 54 (12.1%) N3 202 (13.5%) 148 (14.2%) 54 (12.1%) N4 202 (13.5%) 148 (14.2%) 54 (12.1%) N3 202 (13.5%) 148 (14.2%) 54 (12.1%) N4 202 (13.5%) 148 (14.2%) 54 (12.1%) N4 207 (13.5%) 10 (91.5%) 61 (13.5%) Motastais 76 (52.2%) 10 (91.5%) 61 (13.5%) M1 170 (28.0%) 96 (92.4%) 410 (91.5%) 61 (13.5%) M14 147 (28.4%) 96 (92.4%) 410 (91.5%) 61 (13.5%) Midele site 54 (36.7%) 37 (35.7%) 167 (37.3%) 61 (13.5%) Midele site 54 (36.7%) 167 (60.5%) 175 (39.1%) 62 (13.5%) Vertaping/NOS 21 (15.5%) 304 (29.1%) 123 (27.5%)	T4	304 (20.4%)	212 (20.3%)	92 (20.5%)	
N0 767 (51.4%) 537 (51.4%) 230 (51.3%) N1 317 (21.2%) 213 (20.4%) 104 (23.2%) N2 202 (13.5%) 148 (14.2%) 54 (12.1%) N3 207 (13.9%) 147 (14.1%) 60 (13.4%) Metastasis 50 (71.3%) 60 (24.4%) 60 (13.4%) M1 137 (92.2%) 96 (92.4%) 410 (91.5%) M1 117 (7.8%) 79 (7.6%) 38 (8.5%) Primary site 57 (38.4%) 96 (92.4%) 42 (9.4%) Cardia 140 (9.4%) 98 (9.4%) 42 (9.4%) Distal site 57 (38.4%) 407 (38.9%) 167 (37.3%) Overlapping/NOS 131 (5.5%) 167 (37.3%) 57 (39.1%) Overlapping/NOS 231 (5.5%) 167 (37.3%) 57 (39.1%) Scard 443 (36.7%) 37 (35.7%) 167 (37.3%) Current size 57 (28.6%) 304 (29.1%) 153 (35.7%) Scard 42 (30.9%) 304 (29.1%) 153 (35.7%) Scard 604 (40.5%) 409 (39.1%) 130 (29	N stage				0.509
N1317 (21.2%)213 (20.4%)104 (23.2%)N202 (13.5%)148 (14.2%)54 (12.1%)N307 (13.9%)147 (14.1%)60 (13.4%)Metastais137 (62.2%)96 (92.4%)410 (91.5%)M1117 (7.8%)79 (7.6%)38 (8.5%)Primary site117 (7.8%)98 (9.4%)42 (9.4%)Cardia140 (9.4%)98 (9.4%)42 (9.4%)Dista site54 (36.3%)407 (38.9%)167 (37.3%)Midels site54 (36.7%)33 (35.7%)167 (37.3%)Overlapping/NOS215 (55.0%)167 (16.0%)123 (27.5%)Scm604 (40.5%)340 (9.1%)123 (27.5%)Scm604 (40.5%)332 (31.8%)130 (29.0%)Scm614 (3.0%)332 (31.8%)130 (29.0%)RNE151 (16.2%)110 (10.5%)43 (6.4%)1-15639 (42.8%)101 (15.5%)164 (43.9%)	NO	767 (51.4%)	537 (51.4%)	230 (51.3%)	
N2 202 (13.5%) 148 (14.2%) 54 (12.1%) N3 207 (13.9%) 147 (14.1%) 60 (13.4%) Metastasis	N1	317 (21.2%)	213 (20.4%)	104 (23.2%)	
N3 207(13.9%) 147 (14.1%) 60 (13.4%) Metastasis	N2	202 (13.5%)	148 (14.2%)	54 (12.1%)	
Metastasis0.615M01376 (92.%)96 (92.4%)410 (91.5%)M117 (7.8%)70 (7.6%)38 (8.5%)Primarysite17 (7.8%)88 (9.4%)42 (9.4%)Cardia140 (9.4%)80 (9.4%)167 (37.3%)Distal site574 (38.4%)407 (38.5%)167 (37.3%)Middle site54 (36.7%)373 (35.7%)64 (14.3%)Overlapping/NOS23 (15.5%)167 (16.0%)64 (14.3%)Tumor size122242 (28.6%)304 (29.1%)133 (27.5%)<2 cm	N3	207 (13.9%)	147 (14.1%)	60 (13.4%)	
M0 1376 (92.2%) 966 (92.4%) 410 (91.5%) M1 117 (7.8%) 70 (7.6%) 38 (8.5%) Primarysite	Metastasis				0.615
M1 117(7.8%) 79(7.6%) 38(8.5%) Primary site 0.619 Cardia 140 (9.4%) 98 (9.4%) 42 (9.4%) Distal site 574 (38.4%) 407 (38.9%) 167 (37.3%) Middle site 548 (36.7%) 373 (35.7%) 155 (39.1%) Overlapping/NOS 21 (15.5%) 167 (16.0%) 64 (14.3%) Tumor size 22 cm 427 (28.6%) 304 (29.1%) 123 (27.5%) <2 cm	MO	1376 (92.2%)	966 (92.4%)	410 (91.5%)	
Primary site 0.619 Cardia 140 (9.4%) 98 (9.4%) 42 (9.4%) Distal site 574 (38.4%) 407 (38.9%) 167 (37.3%) Middle site 548 (36.7%) 373 (35.7%) 157 (39.1%) Overlapping/NOS 231 (15.5%) 167 (16.0%) 64 (14.3%) Tumor size 22 cm 427 (28.6%) 304 (29.1%) 123 (27.5%) <2 cm	M1	117 (7.8%)	79 (7.6%)	38 (8.5%)	
Cardia140 (9.4%)98 (9.4%)42 (9.4%)Distal site574 (38.4%)407 (38.9%)167 (37.3%)Middle site548 (36.7%)373 (35.7%)175 (39.1%)Overlapping/NOS231 (15.5%)167 (16.0%)64 (14.3%)Tumor size $22 cm$ 427 (28.6%)304 (29.1%)123 (27.5%)<2 cm	Primary site				0.619
Distal site 574 (38.4%) 407 (38.9%) 167 (37.3%)Middle site 548 (36.7%) 373 (35.7%) 175 (39.1%)Overlapping/NOS 231 (15.5%) 167 (16.0%) 64 (14.3%)Tumor size 0.279 ≤ 2 cm 427 (28.6%) 304 (29.1%) 123 (27.5%) ≤ 5 cm 604 (40.5%) 409 (39.1%) 195 (43.5%) >5 cm 604 (40.5%) 409 (39.1%) 195 (43.5%) >5 cm 604 (40.5%) 322 (31.8%) 130 (29.0%)RNE 0.765 >16 701 (47.0%) 485 (46.4%) 216 (48.2%)0 153 (10.2%) 110 (10.5%) 43 (9.6%)1-15 639 (42.8%) 450 (43.1%) 189 (42.2%)	Cardia	140 (9.4%)	98 (9.4%)	42 (9.4%)	
Middle site548 (36.7%)373 (35.7%)175 (39.1%)Overlapping/NOS231 (15.5%)167 (16.0%)64 (14.3%)Tumor size 0.279 ≤ 2 cm427 (28.6%)304 (29.1%)123 (27.5%) ≤ 5 cm604 (40.5%)409 (39.1%)195 (43.5%) > 5 cm604 (40.5%)332 (31.8%)130 (29.0%) RNE 0.765 >16701 (47.0%)485 (46.4%)216 (48.2%)0153 (10.2%)110 (10.5%)43 (9.6%)1-15639 (42.8%)450 (43.1%)189 (42.2%)	Distal site	574 (38.4%)	407 (38.9%)	167 (37.3%)	
Overlapping/NOS231 (15.5%)167 (16.0%)64 (14.3%)Tumor size0.279≤2 cm427 (28.6%)304 (29.1%)123 (27.5%)≤5 cm604 (40.5%)409 (39.1%)195 (43.5%)>5 cm462 (30.9%)332 (31.8%)130 (29.0%)RNE701 (47.0%)485 (46.4%)216 (48.2%)0153 (10.2%)110 (10.5%)43 (9.6%)1-15639 (42.8%)450 (43.1%)189 (42.2%)	Middle site	548 (36,7%)	373 (35.7%)	175 (39.1%)	
Tumor size 0.279 ≤2 cm 427 (28.6%) 304 (29.1%) 123 (27.5%) ≤5 cm 604 (40.5%) 409 (39.1%) 195 (43.5%) >5 cm 462 (30.9%) 332 (31.8%) 130 (29.0%) RNE 0.765 >16 701 (47.0%) 485 (46.4%) 216 (48.2%) 0 153 (10.2%) 110 (10.5%) 43 (9.6%) 1-15 639 (42.8%) 450 (43.1%) 189 (42.2%)	Overlapping/NOS	231 (15.5%)	167 (16.0%)	64 (14.3%)	
≤2 cm 427 (28.6%) 304 (29.1%) 123 (27.5%) ≤5 cm 604 (40.5%) 409 (39.1%) 195 (43.5%) >5 cm 462 (30.9%) 332 (31.8%) 130 (29.0%) RNE 0.765 >16 701 (47.0%) 485 (46.4%) 216 (48.2%) 0 153 (10.2%) 110 (10.5%) 43 (9.6%) 1-15 639 (42.8%) 450 (43.1%) 189 (42.2%)	Tumor size				0.279
≤5 cm 604 (40.5%) 409 (39.1%) 195 (43.5%) >5 cm 462 (30.9%) 332 (31.8%) 130 (29.0%) RNE 0.765 >16 701 (47.0%) 485 (46.4%) 216 (48.2%) 0 153 (10.2%) 110 (10.5%) 43 (9.6%) 1−15 639 (42.8%) 450 (43.1%) 189 (42.2%)	<2 cm	427 (28.6%)	304 (29 1%)	123 (27 5%)	
>5 cm 462 (30.9%) 332 (31.8%) 130 (29.0%) RNE	<5 cm	604 (40.5%)	409 (39 1%)	195 (43 5%)	
RNE 0.765 >16 701 (47.0%) 485 (46.4%) 216 (48.2%) 0 153 (10.2%) 110 (10.5%) 43 (9.6%) 1-15 639 (42.8%) 450 (43.1%) 189 (42.2%)	>5 cm	462 (30.9%)	332 (31.8%)	130 (29.0%)	
>16 701 (47.0%) 485 (46.4%) 216 (48.2%) 0 153 (10.2%) 110 (10.5%) 43 (9.6%) 1-15 639 (42.8%) 450 (43.1%) 189 (42.2%)	RNF	102 (30.370)	552 (51.070)	100 (20.070)	0.765
No No No No No 0 153 (10.2%) 110 (10.5%) 43 (9.6%) 1-15 639 (42.8%) 450 (43.1%) 189 (42.2%)	>16	701 (47 0%)	485 (46 4%)	216 (48 2%)	0.705
1-15 639 (42.8%) 450 (43.1%) 189 (42.2%)	0	153 (10 20%)	110 (10 50%)	270 (70.270) 27 (0.6%)	
ل (۲۵٫۷۵) ۲۵۷ (۲۵٫۱۳۵) ۲۵۶ (۲۵٫۷۵) ۲۵۶ (۲۵٫۲۳۵)	1_15	630 (42 804)	A50 (A2 10%)	180 (17 70%)	
Radiation 0.267	Radiation	057 (72.070)	(UV 1.CF) UCF	102 (72.270)	0.267

Table 1 The basic characteristics of GNEC patients in the training and validation group

Characteristics	All	Training	Validation	P value	
	N=1493	N=1045	N=448		
None	1170 (78.4%)	826 (79.0%)	344 (76.8%)		
Yes	323 (21.6%)	219 (21.0%)	104 (23.2%)		
Chemotherapy				0.967	
None	906 (60.7%)	635 (60.8%)	271 (60.5%)		
Yes	587 (39.3%)	410 (39.2%)	177 (39.5%)		

Table 1 (continued)

(Fig. 2). The patient's overall risk score was calculated by summing the relevant scores of each risk factor at various levels, representing the patient's likelihood of CSS.

The C-indexes were 0.792 (95% CI: 0.770–0.813) and 0.782 (95% CI: 0.749–0.815), respectively, for the training and internal validation groups. The DCA, calibration, and receiver operating characteristic (ROC) curves were displayed in Figs. 3, 4 and 5. The ROC curves demonstrated that the nomogram exhibited excellent prediction performance (1-, 3-, and 5-year AUC for the training group were 0.81, 0.84, and 0.86; and 1-, 3-, and 5-year AUC for the internal validation cohort were 0.80, 0.84, and 0.85; Fig. 3). Additionally, outstanding therapeutic applications and good positive net benefits were demonstrated by the DCA plots at 1-, 3-, and 5-year in both groups (Fig. 4).

The projected CSS rates at 1-, 3-, and 5-year were highly consistent with the results as shown by the calibration curves (Fig. 5). With the use of the C-index, NRI, and IDI, we compared the applicable values between the nomogram and AJCC system. The nomogram-related C-index in the training cohort was greater than the AJCC threshold (Fig. 6). The NRI was 0.21 (95% CI: 0.10–0.49), 0.29 (95% CI: 0.15–0.51), and 0.37 (95% CI: 0.19–0.55) for the 1-, 3-, and 5-year, respectively. The IDI values were 0.10 (95% CI: 0.07–0.15, P<0.001), 0.12 (95% CI: 0.09–0.17, P<0.001), and 0.13 (95% CI: 0.08–0.18, P<0.001) at 1-, 3-, and 5-year, respectively (Table 3).

The outcomes provided compelling evidence that the nomogram outperformed the AJCC stage system regarding application value and predictive ability.

New Risk Stratification

GNEC patients were divided into three risk cohorts based on the examination of the X-tile software: low risk (46.0 < total points < 204.5), middle risk (204.5 < total points < 330.2), and high risk (330.2 < total points < 437.6; Fig. 7). KM curves demonstrated a significant degree of discrimination among the three risk categories (Fig. 8A and B).

Compared with the new risk stratification, the stage I and stage II patients couldn't be well distinguished in the AJCC staging system. The limited ability to discriminate between stage III and stage IV was also presented (Fig. 8 C and 8D).

External validation of the nomogram

Based on the patient's data acquired from our institution, external validation was performed to further verify the model's effectiveness. The ROC curves demonstrated good prediction performance (1-, 3-, and 5-year AUC were 0.85, 0.86, and 0.94, Fig. 9A) of the nomogram. The calibration curves also presented approximate consistency between the predicted and actual results (Fig. 9B). The nomogram's good clinical practical utility was next confirmed by DCA curves (Fig. 9 C and 9D).

Discussion

Currently, the low incidence rate and high heterogeneity hindered further investigation of GNEC [15]. Thus, we created and validated a nomogram to predict the 1-, 3-, and 5-year CSS of surgical GNEC patients based on the SEER database. The model demonstrated improved prediction ability compared with the 8th AJCC criteria. We then developed a novel risk stratification system that divided all cases into low-, middle-, and high-risk groups and showed a more remarkable ability to distinguish different risk groups than the conventional AJCC staging system by using X-tile software to determine the cutoff value for the best grouping.

Based on the univariate and multivariate Cox regression analysis, ten parameters (age, gender, grade, T stage, N stage, metastasis, primary site, tumor size, RNE, and chemotherapy) significantly affecting CSS in postoperative GNEC patients were enrolled in the predictive nomogram. By examining the max points of the integrated parameters in the model, grade and TNM stage were regarded as highly significant variables influencing the prognoses. Previous research had shown how these risk variables and GNEC were related. Hu et al. investigated current GNEC epidemiological trends and developed a nomogram to assess these patients' prognoses. According to the findings, the survival of GNEC was substantially correlated with grade, T, and N staging [12]. Another Chinese study examined the features of 132 Chinese GNEC patients and found that the patients' survival was independently predicted by the size of the tumor, N stage, mitotic index, radical surgery, and adjuvant treatment [7]. Xu et al. conducted a study comparing intestinal-type GC (IGC) and GNEC patients, finding that GNEC patients had a better prognosis than ICG in

Table 2	Univariate and	l multivariate	Cox regression	analysis of CSS fo	r variable in GNEC	patients after surgical resection

Characteristics	Univariate analysis			Multivariate analysis		
	HR	95%CI	P value	HR	95%CI	P value
Age						
≤60	Reference			Reference		
>60	1.34	1.06-1.68	0.014	1.53	1.19-1.96	0.001
Gender						
Female	Reference			Reference		
Male	1.48	1.19-1.84	< 0.001	1.32	1.06-1.65	0.014
Race						
White	Reference					
Non-White	0.95	0.78-1.17	0.65			
Marital status						
Married	Reference					
Unmarried	111	09-136	0 336			
Grade		0.5 1.50	0.000			
	Reference			Reference		
11	407	25-663	< 0.001	1.96	1 17-3 28	0.011
	6.94	4 28-11 26	< 0.001	2.27	1 34-3 84	0.002
IV	12.02	612-236	< 0.001	3.8	1.86-7.74	< 0.002
Tistage	12.02	0.12 25.0	< 0.001	5.0	1.00 7.74	< 0.001
T stage	Poforonco			Poforonco		
тэ	1.46		0.000	1.05	0.66 1.69	0 020
12	1.40	2 / 1 6 9 1	< 0.099	1.00	1 4 2 2	< 0.001
15	4.02	5.41-0.01	< 0.001	2.12	1.4-5.2	< 0.001
14	0.91	0.2/-12.0/	< 0.001	5.52	2.12-5.19	< 0.001
N stage	Defense			Defense		
NU NI	Reference	207 271	.0.001	Reference	1 27 2 6	.0.001
NI	2.77	2.07-3.71	< 0.001	1.89	1.37-2.6	< 0.001
N2	4.82	3.61-6.44	< 0.001	2.59	1.85-3.65	< 0.001
N3	7.98	6.04-10.54	< 0.001	4.4	3.13-6.21	< 0.001
Metastasis						
MO	Reference			Reference		
M1	3.57	2./1-4.69	< 0.001	2.55	1.8/-3.4/	< 0.001
Primary site						
Cardia	Reference			Reference		
Distal site	0.62	0.45–0.84	0.002	0.52	0.37–0.73	< 0.001
Middle site	0.52	0.38–0.72	< 0.001	0.56	0.39–0.79	0.001
Overlapping/NOS	0.45	0.31–0.67	< 0.001	0.38	0.25–0.59	< 0.001
Tumor size						
≤2 cm	Reference			Reference		
≤5 cm	3.99	2.78-5.73	< 0.001	1.63	1.08–2.46	0.019
>5 cm	7.1	4.97-10.15	< 0.001	1.99	1.29-3.08	0.002
RNE						
>16	Reference			Reference		
0	0.31	0.19–0.52	< 0.001	1.77	1.01-3.09	0.046
1–15	1.05	0.85-1.28	0.672	1.63	1.31-2.03	< 0.001
Radiation						
No	Reference			Reference		
Yes	1.4	1.12–1.75	0.003	0.93	0.71-1.22	0.594
Chemotherapy						
No	Reference			Reference		
Yes	2.05	1.68-2.51	< 0.001	0.67	0.52-0.87	0.002

Fig. 2 A predictive nomogram for postoperative GNEC patients

Fig. 3 ROC of the nomogram for 1-, 3-, and 5-year CSS prediction. (A) Training cohorts; (B) Internal validation cohorts

the early stages of the tumor. Furthermore, age, gender, tumor size, AJCC stage, T stage, N stage, and surgery were all substantially associated with the overall survival of GNEC patients [16]. Concordantly, the Cox regression analysis proposed in our study also identified old age, gender of male, larger tumor size, and higher TNM stage as independent risk variables for CSS. Larger tumor size and higher TNM stage usually indicated more aggressive tumor behavior with worse survival. Age was also a risk factor, which might be attributed to the factor that elderly patients had worse general conditions and suffered more chronic diseases. The nomogram model included risk factors that were easily gotten and collected from the patient's hospitalization information. By using the variable score, clinicians could predict the prognosis accurately and evaluate the treatment benefits. This provided a visual means of communication between clinicians and patients. Through the nomogram chart, patients could know their own probability of survival, which would prompt them to make more reasonable treatment choices. Besides, several variables with higher scores, such as older age and gender of male, should be concerned for the relatively poor prognosis.

It was reported that GNEC patients presented irresponsiveness to traditional chemotherapy [17]. But based on our analysis, chemotherapy could improve postoperative survival among GNEC after surgical resection, indicating that adjuvant chemotherapy should still be adopted. In China, patients with GNEC were typically treated with the same chemotherapy agents as those

Fig. 4 Calibration curves of 1-, 3- and 5-year CSS. (A) Training cohort; (B) Internal validation cohort

Fig. 5 Decision curve analysis of 1-, 3- and 5-year CSS. (A, C, E) Training cohort; (B, D, F) Internal validation cohort

Fig. 6 C-index analysis. (A) The nomogram related C-index; (B) AJCC staging system related C-index

Table 3 NRI and IDI of the nomogram and AJCC staging criteria alone in CSS prediction for postoperative GNEC patients

Index	Training cohort		P value	Validation cohort		P value
	Estimate	95% CI		Estimate	95% Cl	
NRI						
For 1-year CSS	0.21	0.10-0.49		0.17	0.03-0.50	
For 3-year CSS	0.29	0.15-0.51		0.311	0.12-0.63	
For 5-year CSS	0.37	0.19-0.55		0.32	0.28-0.67	
IDI						
For 1-year CSS	0.1	0.07-0.15	< 0.001	0.21	0.15-0.31	< 0.001
For 3-year CSS	0.12	0.09-0.17	< 0.001	0.18	0.12-0.26	< 0.001
For 5-year CSS	0.13	0.08-0.18	< 0.001	0.17	0.10-0.25	< 0.001

Fig. 7 Cut-off point for risk stratification selected using X-tile

with gastric adenocarcinoma, including fluorouracil, cisplatin, streptomycin, allium annulus, and paclitaxel [18, 19]. Therefore, specific chemotherapeutic drugs and regimens for GNEC should be further explored. In addition, as shown in the model, the primary site of cardia was correlated with poorer prognoses. GC could be divided into cardia and non-cardia according to the tumor location, which presented different epidemiology and tumor behavior [20]. And GC patients with cardia invasion tended to suffer worse survival in previous studies [21]. So, our research first validated that the primary site of cardia was a risk factor in postoperative GNEC patients.

Currently, the AJCC TNM staging system is the main option for cancer prognosis prediction. However, its application in GNEC patients has recently been called into question [7]. It was reported that other clinical parameters, such as gender, grade, and adjuvant therapy, were significantly related to the prognoses of GNEC patients [22-24]. So, we created a nomogram by combining various factors (such as demographic and clinicopathologic traits) affecting CSS in patients with GNEC. Additionally, depending on their overall scores, patients were categorized into low-, middle-, and highrisk groups. On this premise, it was possible to compare the power of the nomogram with the conventional AJCC staging system, which was not performed in the previous research. The nomogram demonstrated better predictive ability than tumor staging based solely on AJCC criteria, according to the NRI, IDI, and C-index data. Besides, the effectiveness of the predictive model was tested in both the internal validation and external validation cohorts. According to the KM curves, the stage I and stage II

Fig. 8 KM analyses of postoperative GNEC patients. (A, B) KM curves of training and internal validation cohorts based on the new risk stratification system; (C, D) KM curves of training and internal validation cohorts based on AJCC staging criteria

Fig. 9 Results of the external validation cohort. (A) ROC for 1-, 3-, and 5-year CSS prediction. (B) Calibration curves of 1-, 3- and 5-year CSS. (C, D) Decision curve analysis of 1-, 3-year CSS

patients couldn't be well distinguished in the AJCC staging system. The limited ability to discriminate between stage III and stage IV was also presented. Surprisingly, compared to the conventional staging system, the KM analysis showed significantly different CSS among the three risk groups, which can help clinicians customize their management and treatment plans.

Limitation

The current study included various limitations due to the nature of the database, which should be considered when interpreting the results. To begin, because this was a retrospective study, selection bias was unavoidable. Second, the SEER database lacked information on precise data on performance status, comorbidities, varied chemotherapy regimens, treatment for distant metastases, somatostatin analogues, and "neuroendocrine cancer-specific" data. Furthermore, the SEER database's GNEC classification was not completely the same as the WHO classification. Finally, even though the research was externally validated, the small sample data could only provide limited support for the result. Multicenter data with a larger sample size are required to further evaluate the predictive model.

Conclusion

In summary, we constructed and validated a nomogram to predict 1-, 3-, and 5-year CSS for GNEC patients after surgical resection. The prognostic factors identified in the model could help doctors better understand the rare malignancy and enhance the treatment plan. Larger and multicenter samples are required to assess and validate its performance and broaden its applicability.

Acknowledgements

Not applicable.

Authors' contributions

Lou YF designed the study; Song X performed the major statistical analysis and drafted the manuscript. Xie YY collected the data and searched the literature. All authors contributed to the article and approved the final version of the manuscript.

Funding

Not applicable.

Data Availability

The datasets created and evaluated during this project are housed in the SEER database (https://seer.cancer.gov/). Yafang Lou could be reached for study data upon reasonable request.

Declarations

Ethics approval and consent to participate

We certified that all methods were carried out in line with the Helsinki Declaration. Because the patient data obtained from the SEER database is publicly accessible, no ethical approval was required. The Hangzhou TCM Hospital's Ethics Committee evaluated and authorized the experiment involving human subjects. The ethics committee waived informed consent for this retrospective investigation.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 5 April 2023 / Accepted: 7 July 2023 Published online: 14 July 2023

References

- Oue N, Sentani K, Sakamoto N, Uraoka N, Yasui W. Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and cancer stem cells. Int J Clin Oncol. 2019;24(7):771–8.
- Iwamoto M, Gotoda T, Noda Y, Esaki M, Moriyama M, Yoshida N, et al. Gastric neuroendocrine carcinoma with Rapid Progression. Intern Med. 2020;59(10):1271–6.
- Xie J, Zhao Y, Zhou Y, He Q, Hao H, Qiu X, et al. Predictive value of combined preoperative Carcinoembryonic Antigen Level and Ki-67 index in patients with gastric neuroendocrine carcinoma after radical surgery. Front Oncol. 2021;11:533039.
- 4. Facciorusso A, Straus Takahashi M, Eyileten Postula C, Buccino V, Muscatiello N. Efficacy of hemostatic powders in upper gastrointestinal bleeding: a systematic review and meta-analysis. Digestive and liver disease: official journal of the italian society of Gastroenterology and the Italian Association for the study of the liver. 2019;51(12):1633–40.
- Lin J, Zhao Y, Zhou Y, Tian Y, He Q, Lin J, et al. Comparison of survival and patterns of recurrence in gastric neuroendocrine carcinoma, mixed Adenoneuroendocrine Carcinoma, and Adenocarcinoma. JAMA Netw Open. 2021;4(7):e2114180.
- Xie J, Lu J, Lin J, Zheng C, Li P, Wang J, et al. Different long-term oncologic outcomes after radical surgical resection for neuroendocrine carcinoma and adenocarcinoma of the stomach. Oncotarget. 2017;8(34):57495–504.
- Xie JW, Sun YQ, Feng CY, Zheng CH, Li P, Wang JB, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42(10):1464–70.
- Xie JW, Li P, Wang JB, Lin JX, Lu J, Chen QY, et al. Modified AJCC staging of gastric neuroendocrine carcinoma based on T staging can improve the capacity of prognosis assessment. J Cancer Res Clin Oncol. 2018;144(12):2391–7.
- 9. Zhong Q, Chen QY, Xie JW, Wang JB, Lin JX, Lu J et al. Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: a large population-based study. Cancer Med. 2018.
- Callahan A, White M, Ituarte P, Gagandeep S, Woo Y, Fong Y, et al. Surgical intervention in gastric carcinoid is Associated with Improved Survival in Local and Regional Disease. Am J Clin Oncol. 2018;41(9):882–7.
- Fang C, Wang W, Zhang Y, Feng X, Sun J, Zeng Y, et al. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. Chin J Cancer. 2017;36(1):51.
- Hu P, Bai J, Liu M, Xue J, Chen T, Li R, et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric Cancer. 2020;23(4):591–9.
- Li J, Lin Y, Wang Y, Lin H, Lin F, Zhuang Q et al. Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis. ESMO Open. 2020;5(2).
- Li Z, Ren H, Wang T, Zhang X, Zhao L, Sun C, et al. Resection of the primary Tumor improves the survival of patients with stage IV gastric neuroendocrine carcinoma. Front Oncol. 2022;12:930491.
- 15. Liang W, Yi-Xu X-C. Jian-Bo. Neuroendocrine carcinoma of the stomach: clinical features and CT findings.
- Xu B, Chu Y, Hu Q, Song Q. The clinicopathological features and overall survival of patients with gastric neuroendocrine carcinoma. Technol Cancer Res Treat. 2021;20:15330338211055340.
- Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol. 2020;12(8):791–807.
- Xiao LY, Kan WM. Cyclic AMP (cAMP) confers drug resistance against DNA damaging agents via PKAIA in CML cells. Eur J Pharmacol. 2017;794:201–8.
- Hasan S, Taha R, Omri HE. Current opinions on Chemoresistance: an overview. Bioinformation. 2018;14(2):80–5.

- 20. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–13.
- Kim YJ, Chung WC, Cho IH, Kim J, Kim S. Prognostic effect of different etiologies in patients with gastric cardia cancer. Med (Baltim). 2019;98(50):e18397.
- Sackstein PE, O'Neil DS, Neugut AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018;45(4):249–58.
- 23. Merath K, Bagante F, Beal EW, Lopez-Aguiar AG, Poultsides G, Makris E, et al. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors:

an analysis of the U.S. Neuroendocrine Tumor Study Group. J Surg Oncol. 2018;117(5):868–78.

 McMullen T, Al-Jahdali A, de Gara C, Ghosh S, McEwan A, Schiller D. A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours. Can J Surg. 2017;60(3):192–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.